Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance

BACKGROUND: Non-small cell lung cancer (NSCLC) patients with activating EGFR mutations initially respond to first-generation EGFR inhibitors; however, the efficacy of these drugs is limited by acquired resistance driven by the EGFR (T790M) mutation. The discovery of third-generation EGFR inhibitors...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Tao, Qu, Rong, Chan, Shingpan, Lai, Mengzhen, Tong, Linjiang, Feng, Fang, Chen, Hongyu, Song, Tingting, Song, Peiran, Bai, Gang, Liu, Yingqiang, Wang, Yanan, Li, Yan, Su, Yi, Shen, Yanyan, Sun, Yiming, Chen, Yi, Geng, Meiyu, Ding, Ke, Ding, Jian, Xie, Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7218543/
https://www.ncbi.nlm.nih.gov/pubmed/32404161
http://dx.doi.org/10.1186/s12943-020-01202-9

Ejemplares similares

Ejemplares similares